Lipocine INC 8-K filings

Lipocine Inc. announced the filing of an updated corporate presentation, which will be used for investor and analyst meetings.

Lipocine Inc. announced the dosing of the first patient in its Phase 3 clinical trial for LPCN 1154, an investigational oral treatment for postpartum depression, with top-line results expected in Q2 2026.

Lipocine Inc. announced it will host a virtual R&D investor event on July 9, 2025, to discuss its lead clinical program, LPCN 1154 (BRLIZIO), as a potential treatment for postpartum depression, featuring a leading expert in the field.

Lipocine Inc. announced that its licensing partner, Verity Pharma, has filed a New Drug Submission for TLANDO, an oral testosterone replacement therapy, in Canada, targeting a significant market opportunity.

Lipocine Inc. announced the successful approval and filing of an amendment to its Certificate of Incorporation, significantly reducing the number of authorized common shares from 200 million to 75 million, alongside the election of directors and other key corporate governance matters at its annual shareholder meeting.

Lipocine Inc. announces that its drug candidate LPCN 1148, targeting sarcopenia and hepatic encephalopathy in men with cirrhosis, is featured in the June 2025 edition of Hepatology.

Lipocine Inc. will present at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025, to discuss its biopharmaceutical developments.

Lipocine Inc. has updated its corporate presentation for meetings with investors and analysts, as detailed in a new SEC filing.

Lipocine reports Q1 2025 financial results, including a net loss of $1.9 million, and provides updates on its drug development programs and partnerships.

Lipocine has granted Ach Laboratórios Farmacêuticos S.A. exclusive rights to market TLANDO in Brazil, a rapidly growing market for testosterone replacement therapy.

Lipocine Inc. has updated its corporate presentation for meetings with investors and analysts, as detailed in a Form 8-K filing.

Lipocine Inc. has commenced a Phase 3 clinical trial for LPCN 1154, an oral formulation of brexanolone, aimed at treating postpartum depression (PPD).

Lipocine reports a net income for 2024, driven by license and royalty revenue, and provides updates on its drug development programs.

Lipocine announces that the FDA has informed sponsors of approved testosterone products about class-wide labeling changes based on the TRAVERSE trial and post-market ABPM studies.

Lipocine Inc. has updated its corporate presentation for meetings with investors and analysts, as detailed in a Form 8-K filing.

Lipocine announces revised regulatory guidance from the FDA for LPCN 1154, a treatment for postpartum depression, now requiring an efficacy and safety study for NDA submission.

Lipocine Inc. has updated its corporate presentation for meetings with investors and analysts, as detailed in a Form 8-K filing.

The FDA has granted Fast Track Designation to Lipocine's LPCN 1148 for treating sarcopenia in patients with decompensated cirrhosis, potentially expediting its development and review.

Lipocine Inc. has updated its corporate presentation for use in meetings with investors and analysts.

Lipocine's LPCN 1148 shows significant improvements in sarcopenia and hepatic encephalopathy in a Phase 2 trial for patients with cirrhosis.

Lipocine reported a reduced net loss for the third quarter of 2024 and provided updates on its drug development programs and partnerships.

Lipocine Inc. presented a poster at the Obesity Society's Annual Obesity Week conference, highlighting that oral LPCN 2401 reduces fat mass and increases lean mass in men with obesity.

Lipocine has entered into a distribution and license agreement with SPC Korea to commercialize its TLANDO product in South Korea for testosterone replacement therapy.

Lipocine Inc. has extended its stockholder rights plan to October 22, 2027, and amended the designation of its Series A Junior Participating Preferred Stock to reflect a prior reverse stock split.

Lipocine Inc. held a virtual key opinion leader event on October 16, 2024, focusing on LPCN 2401 for improved body composition in obesity management.

Lipocine reports positive Phase 1 study results for oral brexanolone, showing robust central nervous system activity and supporting its development for neuropsychiatric disorders.

Lipocine has entered into an exclusive supply and distribution agreement with Pharmalink to commercialize its oral testosterone replacement therapy, TLANDO, in the Gulf Cooperation Council (GCC) countries.

Lipocine Inc. presented an investor presentation at the H.C. Wainwright 8th Annual MASH Investor Conference on October 7, 2024.

Lipocine Inc. announces a virtual key opinion leader event on October 16, 2024, to discuss LPCN 2401 for improved body composition in obesity management.

Lipocine Inc. will present and meet with investors at the H.C. Wainwright 8th Annual MASH Investor Conference on October 7, 2024.